[go: up one dir, main page]

ATE365922T1 - Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) - Google Patents

Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)

Info

Publication number
ATE365922T1
ATE365922T1 AT01982003T AT01982003T ATE365922T1 AT E365922 T1 ATE365922 T1 AT E365922T1 AT 01982003 T AT01982003 T AT 01982003T AT 01982003 T AT01982003 T AT 01982003T AT E365922 T1 ATE365922 T1 AT E365922T1
Authority
AT
Austria
Prior art keywords
ovarian cancer
human kallikrein
detecting ovarian
binds
subject
Prior art date
Application number
AT01982003T
Other languages
English (en)
Inventor
Eleftherios Diamandis
Original Assignee
Mount Sinai Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai Hospital Corp filed Critical Mount Sinai Hospital Corp
Application granted granted Critical
Publication of ATE365922T1 publication Critical patent/ATE365922T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01982003T 2000-10-27 2001-10-26 Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) ATE365922T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24378900P 2000-10-27 2000-10-27

Publications (1)

Publication Number Publication Date
ATE365922T1 true ATE365922T1 (de) 2007-07-15

Family

ID=22920140

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01982003T ATE365922T1 (de) 2000-10-27 2001-10-26 Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)

Country Status (9)

Country Link
US (1) US20040096915A1 (de)
EP (1) EP1330652B1 (de)
JP (1) JP2004511810A (de)
AT (1) ATE365922T1 (de)
AU (1) AU2002213704A1 (de)
CA (1) CA2426286A1 (de)
DE (1) DE60129151T2 (de)
ES (1) ES2287169T3 (de)
WO (1) WO2002035232A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
AU8738401A (en) * 2000-08-11 2002-02-25 Mount Sinai Hospital Corp Novel kallikrein gene
EP1332367A2 (de) * 2000-11-01 2003-08-06 Mount Sinai Hospital Nachweis von eierstockkrebs
JP2004530884A (ja) * 2001-05-25 2004-10-07 マウント・シナイ・ホスピタル Ｅｐｈｂ２のキナーゼドメインを調節する方法
WO2003034068A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Localization of disorders associated with kallikreins
US20050176002A1 (en) * 2001-10-16 2005-08-11 Mount Sinai Hospital Methods for detecting ovarian cancer
WO2004021009A2 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
CA2497058A1 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
CA2499261A1 (en) * 2002-09-26 2004-04-08 Mount Sinai Hospital Methods for detecting endocrine cancer
CA2516591A1 (en) * 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
WO2004077060A2 (en) * 2003-02-27 2004-09-10 Mount Sinai Hospital Assay for detection of renal cell carcinoma
CA2468651A1 (en) * 2003-06-13 2004-12-13 Eleftherios P. Diamandis Detection of neurodegenerative diseases
US20060269971A1 (en) * 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
JP4682152B2 (ja) * 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
WO2005078117A2 (en) * 2004-02-18 2005-08-25 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)
DE102005004294A1 (de) * 2005-01-28 2006-08-03 Bayer Healthcare Ag Auswahl und Bewertung diagnostischer Tests mittels Diskordanzanalysen-Charakteristik (DAC)
EP2087152B1 (de) * 2006-10-27 2015-03-11 Walfish, Paul Endometriale biomarker
EP2271917A1 (de) * 2008-04-09 2011-01-12 Smiths Detection Inc. Mehrdimensionale spektralanalyse zur verbesserten identifikation und bestätigung von radioaktiven isotopen
US7851230B2 (en) * 2008-04-14 2010-12-14 Chang Gung Memorial Hospital Stress-induced phosphoprotein 1 as a biomarker for the detection of human ovarian cancers and endometriosis
CA2787027A1 (en) 2010-01-13 2011-07-21 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Detection of gastrointestinal disorders
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
EP2556172A4 (de) 2010-04-06 2013-10-30 Caris Life Sciences Luxembourg Holdings Zirkulierende biomarker für krankheiten
EP2721417A4 (de) * 2011-06-17 2015-05-06 Univ Arkansas Neue marker zur frühdiagnose von eierstockkrebs, überwachung während der entsprechenden therapie und neue therapieoptionen während und nach der entsprechenden chemotherapie
CN103675278A (zh) * 2013-11-19 2014-03-26 上海裕隆医学检验所股份有限公司 一种糖链抗原125定量检测试剂盒及其应用
CN107001478B (zh) 2014-10-14 2022-01-11 诺华股份有限公司 针对pd-l1的抗体分子及其用途
EP3888021B1 (de) 2018-11-30 2024-02-21 Caris MPI, Inc. Molekulare profilierung der nächsten generation
AU2020397802A1 (en) 2019-12-02 2022-06-16 Caris Mpi, Inc. Pan-cancer platinum response predictor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
IL105793A0 (en) * 1992-05-28 1993-09-22 Lilly Co Eli Protease and related dna compounds
WO1998011238A2 (en) * 1996-09-13 1998-03-19 Dana-Farber Cancer Institute Protease m, a novel serine protease
US6294344B1 (en) * 1997-03-19 2001-09-25 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US6316213B1 (en) * 1997-03-19 2001-11-13 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian, breast and lung cancer
US6870027B2 (en) * 1997-03-19 2005-03-22 O'brien Timothy J. Methods for the early diagnosis of ovarian cancer
US6268165B1 (en) * 1997-03-19 2001-07-31 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
AU6468998A (en) * 1997-03-19 1998-10-12 Board Of Trustees Of The University Of Arkansas, The Compositions and method for the early diagnosis of ovarian cancer
PT1092767E (pt) * 1998-07-02 2007-01-31 Fuso Pharmaceutical Ind Anticorpo monoclonal específico de protease de serina e sua utilização
US6942978B1 (en) * 1999-03-03 2005-09-13 The Board Of Trustees Of The University Of Arkansas Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US7935531B2 (en) * 2000-02-22 2011-05-03 Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
AU8738401A (en) * 2000-08-11 2002-02-25 Mount Sinai Hospital Corp Novel kallikrein gene
CA2360219A1 (en) * 2000-10-27 2002-04-27 Mount Sinai Hospital Method for detecting alzheimer's disease
JP2004530884A (ja) * 2001-05-25 2004-10-07 マウント・シナイ・ホスピタル Ｅｐｈｂ２のキナーゼドメインを調節する方法
US20050176002A1 (en) * 2001-10-16 2005-08-11 Mount Sinai Hospital Methods for detecting ovarian cancer
CA2481093A1 (en) * 2002-04-04 2003-10-16 Mount Sinai Hospital Methods for detecting ovarian cancer
US20040015745A1 (en) * 2002-07-22 2004-01-22 Finisar Corporation Scalable socketed testing tool
WO2004021009A2 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
CA2497058A1 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
CA2499261A1 (en) * 2002-09-26 2004-04-08 Mount Sinai Hospital Methods for detecting endocrine cancer
CA2516591A1 (en) * 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
WO2004077060A2 (en) * 2003-02-27 2004-09-10 Mount Sinai Hospital Assay for detection of renal cell carcinoma
CA2468651A1 (en) * 2003-06-13 2004-12-13 Eleftherios P. Diamandis Detection of neurodegenerative diseases
US20060269971A1 (en) * 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer

Also Published As

Publication number Publication date
ES2287169T3 (es) 2007-12-16
WO2002035232A3 (en) 2002-09-26
DE60129151T2 (de) 2008-03-06
DE60129151D1 (de) 2007-08-09
CA2426286A1 (en) 2002-05-02
AU2002213704A1 (en) 2002-05-06
US20040096915A1 (en) 2004-05-20
EP1330652B1 (de) 2007-06-27
EP1330652A2 (de) 2003-07-30
WO2002035232A2 (en) 2002-05-02
JP2004511810A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
WO2002037112A3 (en) Detection of ovarian cancer
SG169395A1 (en) Detection of cancer by elevated levels of bcl-2
BRPI0311233B8 (pt) métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
DK1734368T3 (da) Annexin-autoantistoffer anvendt som markörer for lungecancer
CA2384579A1 (en) Early cancer tumor marker
WO2004055519A3 (en) Specific markers for pancreatic cancer
ATE289685T1 (de) Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
DE60126592D1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
Ghazani et al. Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
HK1088947A1 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
ATE267399T1 (de) Verfahren zum nachweis von komplex-gebundenem prostata-spezifischem antigen (kpsa)
CA2623653A1 (en) Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
AU2003260457A1 (en) A method and kit for the quantitative and/or qualitative detection of components in a sample
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
ATE427494T1 (de) Verfahren zur quantifizierung der akt-protein- expression
WO2007060240A3 (fr) Procede pour la mise en evidence de la presence ou de l ' absence de marquers (eef1a1 ou mark3 ) associes a la presence et/ou a la chimiosensibilite des tumeurs
WO2002004952A3 (en) Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
WO2002063048A3 (en) Methods for predicting sensitivity of tumors to arginine deprivation
WO2005040806A3 (en) Use of protein asc as a marker for breast cancer
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
DE60320821D1 (de)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties